Low dose of infliximab is inadequate in most patients with spondylarthropathies

Clinical and Experimental Rheumatology

Volumn 23, Issue 4, 2005, Pages 513-516

  Sidiropoulos, Prodromos ^b   Kritikos, Herakles D ^b   Siakka, Panagiota ^b   Mamoulaki, Marilena ^b   Kouroumali, Heleni ^b   Voudouris, Kostantinos ^a   Boumpas, Dimitrios T ^b  

^a Aristotle University of Thessaloniki   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

BASDAI; Infliximab; Spondylarthropathy

Indexed keywords

INFLIXIMAB; METHOTREXATE; PREDNISOLONE;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FREQUENCY ANALYSIS; HUMAN; LOW DRUG DOSE; LUNG INFECTION; MALE; PLEURA EFFUSION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEALTH STATUS; HUMANS; MALE; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 26844461121     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. BRAUN J, BOLLOW M, REMLINGER G et al.: Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998; 41: 58-67.
2. BRAUN J, PINCUS T: Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 2002; 20 (Suppl. 28): S16-S22.
3. BRAUN J, SIEPER J: Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res 2002; 4: 307-21.
4. GONZALEZ-LOPEZ L, GARCIA-GONZALEZ A, VAZQUEZ-DEL-MERCADO M, MUNOZ-VALLE JF, GAMEZ-NAVA JI: Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol 2004; 31: 1568-74.
5. MEASE PJ: Cytokine blockers in psoriatic arthritis. Ann Rheum Dis 2001; 60 (Suppl. 3): iii37-40.
6. BRAUX J, BRANDT J, LISTING J et al.: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-193.
7. Van Den BF, KRUITHOF E, BAETEN D et al.: Randomized double-blind comparison of chimeric monoclonal antibody to rumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002; 46: 755-65.
8. ANTONI C, DECHANT C, HANNS-MARTIN LORENZ PD et al.: Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002; 47: 506-12.
9. DOUGADOS M, van der LS, JUHLIN R et al.: The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34: 1218-27.
10. van der LS, VALKENBURG HA, CATS A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
11. BRAUN J, BOLLOW M, NEURE L et al.: Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499-505.
12. ZINK A, BRAUN J, LISTING J, WOLLENHAUPT J: Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 2000; 27: 613-22.
13. MAKSYMOWYCH WP, JHANGRI GS, LAMBERT RG et al.: Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002; 29: 959-65.
14. RUSSELL AS, OROZCO JH, MAKSYMOWYCH WP: The dose of infliximab in the treatment of ankylosing spondylitis: Dollars and sense. Clin Exp Rheumatol 2002; 20 (Suppl. 28): S135-S136.
15. BRAUN J, BRANDT J, LISTING J et al.: Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003; 48: 2224-33.
16. BRAUN J, PHAM T, SIEPER J et al.: International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003; 62: 817-24.
17. BAERT F, NOMAN M, VERMEIRE S et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8.